News

Date
Title
Sort By:
10/06/26
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
09/28/26
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
09/22/26
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
09/15/26
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
09/10/26
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
09/01/26
SCYNEXIS to Participate in Upcoming Investor Conferences
08/25/26
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
08/10/26
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/30/26
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
05/22/26
SCYNEXIS Announces One-for-Eight Reverse Stock Split